Literature DB >> 30508662

Therapeutic strategies for prion disease: a practical perspective.

Brian S Appleby1, Allyson Connor2, Han Wang2.   

Abstract

Human prion diseases are usually rapid neurodegenerative illnesses that are invariably fatal. Despite several clinical trials, no effective treatment has been discovered in humans. Although prior clinical trials have not been successful, they provided information that is vital for the formation of future clinical trials. Among these findings is the realization that there are several prion disease-specific aspects that must be considered when conducting clinical trials. The rarity, rapidity, and clinical heterogeneity of prion disease affect study enrollment and the ability to measure treatment effects. In addition to affecting results, study methodology may also influence study enrollment. In this review, we explore several challenges to conducting clinical trials in prion disease and suggest some practical considerations.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30508662     DOI: 10.1016/j.coph.2018.11.006

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  5 in total

1.  Atypical Case of VV1 Creutzfeldt-Jakob Disease Subtype: Case Report.

Authors:  Adrianna E Carrasco; Brian S Appleby; Ignazio Cali; Hamid R Okhravi
Journal:  Front Neurol       Date:  2022-05-09       Impact factor: 4.086

2.  Clinicopathological findings of an MM2-cortical-type sporadic Creutzfeldt-Jakob disease patient with cortical blindness during a course of glaucoma and age-related macular degeneration.

Authors:  Yuichi Hayashi; Yasushi Iwasaki; Masahiro Waza; Hideaki Shibata; Akio Akagi; Akio Kimura; Takashi Inuzuka; Katsuya Satoh; Tetsuyuki Kitamoto; Mari Yoshida; Takayoshi Shimohata
Journal:  Prion       Date:  2019-01       Impact factor: 3.931

3.  Subtype Diagnosis of Sporadic Creutzfeldt-Jakob Disease with Diffusion Magnetic Resonance Imaging.

Authors:  Alberto Bizzi; Riccardo Pascuzzo; Janis Blevins; Marco E M Moscatelli; Marina Grisoli; Raffaele Lodi; Fabio M Doniselli; Gianmarco Castelli; Mark L Cohen; Aymeric Stamm; Lawrence B Schonberger; Brian S Appleby; Pierluigi Gambetti
Journal:  Ann Neurol       Date:  2020-12-22       Impact factor: 10.422

4.  Development of novel clinical examination scales for the measurement of disease severity in Creutzfeldt-Jakob disease.

Authors:  Akin Nihat; Tze How Mok; Hans Odd; Andrew Geoffrey Bourne Thompson; Diana Caine; Kirsty McNiven; Veronica O'Donnell; Selam Tesfamichael; Peter Rudge; John Collinge; Simon Mead
Journal:  J Neurol Neurosurg Psychiatry       Date:  2022-01-12       Impact factor: 10.154

5.  Clinicopathological findings of a long-term survivor of V180I genetic Creutzfeldt-Jakob disease.

Authors:  Yuichi Hayashi; Yasushi Iwasaki; Masahiro Waza; Shinei Kato; Akio Akagi; Akio Kimura; Takashi Inuzuka; Katsuya Satoh; Tetsuyuki Kitamoto; Mari Yoshida; Takayoshi Shimohata
Journal:  Prion       Date:  2020-12       Impact factor: 3.931

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.